Heart shock drug hope: empagliflozin may cut deaths
NCT ID NCT07450417
First seen Mar 11, 2026 · Last updated Jun 22, 2026 · Updated 18 times
Summary
This study looks at whether starting empagliflozin early in patients with cardiogenic shock (a severe heart pump failure) can lower the chance of death or repeat hospital stays for heart failure within 3 months. Researchers will compare 418 patients who got the drug plus usual care against those who got usual care alone. The goal is to see if this well-tolerated heart failure drug can help in the most critical cases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chru Nancy
Vandœuvre-lès-Nancy, 54500, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
empagliflozin (an SGLT2 inhibitor, a type of diabetes drug also used for heart failure)
What this could lead to
If it works, this could point toward a new treatment to reduce deaths and hospital readmissions for people in cardiogenic shock.
What could go wrong
This is a retrospective study, not a randomized trial, so results may be less reliable. The drug may not show benefit in this very sick population, and kidney risks are a concern.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.